BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14672521)

  • 1. Pharmacogenomics and children: meeting the ethical challenges.
    Freund CL; Clayton EW
    Am J Pharmacogenomics; 2003; 3(6):399-404. PubMed ID: 14672521
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ethics of pharmacogenomics.
    Neil D; Craigie J
    Monash Bioeth Rev; 2004 Apr; 23(2):9-20. PubMed ID: 15810202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging ethical issues in pharmacogenomics: from research to clinical practice.
    Freund CL; Wilfond BS
    Am J Pharmacogenomics; 2002; 2(4):273-81. PubMed ID: 12421098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ethical considerations on pharmacogenomics.
    Mordini E
    Pharmacol Res; 2004 Apr; 49(4):375-9. PubMed ID: 15202517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ethical considerations for pharmacogenomic testing in pediatric clinical care and research.
    Moran C; Thornburg CD; Barfield RC
    Pharmacogenomics; 2011 Jun; 12(6):889-95. PubMed ID: 21692618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using pharmacogenetics and pharmacogenomics in the treatment of psychiatric disorders: some ethical and economic considerations.
    Morley KI; Hall WD
    J Mol Med (Berl); 2004 Jan; 82(1):21-30. PubMed ID: 14598045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Researchers' perceptions of the ethical implications of pharmacogenomics research with children.
    Avard D; Silverstein T; Sillon G; Joly Y
    Public Health Genomics; 2009; 12(3):191-201. PubMed ID: 19204423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethical and public policy challenges for pharmacogenomics.
    Gershon ES; Alliey-Rodriguez N; Grennan K
    Dialogues Clin Neurosci; 2014 Dec; 16(4):567-74. PubMed ID: 25733960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rhetoric and hype: where's the 'ethics' in pharmacogenomics?
    Williams-Jones B; Corrigan OP
    Am J Pharmacogenomics; 2003; 3(6):375-83. PubMed ID: 14672518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Race, distributive justice and the promise of pharmacogenomics: ethical considerations.
    Lee SS
    Am J Pharmacogenomics; 2003; 3(6):385-92. PubMed ID: 14672519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Ethics, politics, and rights in pharmacogenomics].
    Bellver Capella V
    Rev Derecho Genoma Hum; 2002; (17):31-55. PubMed ID: 12703107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Society and ethics - the genetics of disease.
    Thomas SM
    Curr Opin Genet Dev; 2004 Jun; 14(3):287-91. PubMed ID: 15172672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics--legal, ethical and regulatory considerations.
    March R; Cheeseman K; Doherty M
    Pharmacogenomics; 2001 Nov; 2(4):317-27. PubMed ID: 11722282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stakeholder views on pharmacogenomic testing.
    Patel HN; Ursan ID; Zueger PM; Cavallari LH; Pickard AS
    Pharmacotherapy; 2014 Feb; 34(2):151-65. PubMed ID: 24167008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An ethical and legal overview of pharmacogenomics: perspectives and issues.
    Sillon G; Joly Y; Feldman S; Avard D
    Med Law; 2008 Dec; 27(4):843-57. PubMed ID: 19202860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenomics: questions and concerns.
    Mahlknecht U; Voelter-Mahlknecht S
    Curr Med Res Opin; 2005 Jul; 21(7):1041-7. PubMed ID: 16004671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and moral challenges of pharmacogenomics.
    Issa AM
    Natl Cathol Bioeth Q; 2001; 1(4):541-53. PubMed ID: 12854555
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacogenetics: ethical issues and policy options.
    Buchanan A; Califano A; Kahn J; McPherson E; Robertson J; Brody B
    Kennedy Inst Ethics J; 2002 Mar; 12(1):1-15. PubMed ID: 12211263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ethical concerns related to developing pharmacogenomic treatment strategies for addiction.
    Shields AE
    Addict Sci Clin Pract; 2011 Jul; 6(1):32-43. PubMed ID: 22003420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Asymmetry in scientific method and limits to cross-disciplinary dialogue: toward a shared language and science policy in pharmacogenomics and human disease genetics.
    Ozdemir V; Williams-Jones B; Graham JE; Preskorn SH; Gripeos D; Glatt SJ; Friis RH; Reist C; Szabo S; Lohr JB; Someya T
    J Investig Med; 2007 Apr; 55(3):130-41. PubMed ID: 17481382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.